# Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa

> **NCT01693029** · PHASE3 · COMPLETED · sponsor: **Sandoz** · enrollment: 435 (actual)

## Conditions studied

- Anemia
- Chronic Kidney Disease (CKD)

## Interventions

- **DRUG:** HX575 epoetin alfa
- **DRUG:** US-licensed epoetin alfa

## Key facts

- **NCT ID:** NCT01693029
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-05
- **Final completion:** 2015-03
- **Target enrollment:** 435 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01693029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01693029, "Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01693029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*